Philadelphia

Neuroendocrine Tumors | Not so Rare?

Josh Mailman, MBA, the president of NorCal CarciNET, discusses the management of neuroendocrine tumors (NETs) through a patient’s perspective. He reports on overall patients’ attitudes toward Gallium Ga 68-DOTATATE imaging and the newly-approved Lutetium Lu 177 Dotatate therapy, as well as advocacy in the NETs patient community.

Read More

NET Background and Therapy

Arturo Loaiza-Bonilla, MD, MSEd, FACP, explains the basic scientific concepts behind neuroendocrine tumors (NETs), as well as classifying and staging these cancers. He then discusses the rationale behind targeting somatostatin receptors in NETs, therapy options, and future research in this setting.

Read More